Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]

• Autori principali: Ranzenigo M (Autore), Gianotti N (Autore), Galli L (Autore), Poli A (Autore), Mastrangelo A (Autore), Bruzzesi E (Autore), Chiurlo M (Autore), Nozza S (Autore), Bossolasco S (Autore), Spagnuolo V (Autore), Mancusi D (Autore), Termini R (Autore), Carini E (Autore), Lazzarin A (Autore), Castagna A (Autore)
• Natura: Libro
• Pubblicazione: Dove Medical Press, 2022-10-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Ranzenigo M, Gianotti N, Galli L, et al. Drug Des Devel Ther. 2022;16:1975–1982. Page 1975, Abstract, Results, line five, the text “the ongoing regimen was based on NNRTIs in 37 (35%) and on InSTIs in 69 (65%)” should read “the ongoing regimen was based on NNR...